康泰医学(300869.SZ)：持股5%以上股东、部分董事及高管拟减持公司股份

Group 1 - Major shareholder Wang Guili plans to reduce holdings by up to 4,000,000 shares (1.00% of total shares) through centralized bidding and up to 8,000,000 shares (1.99% of total shares) through block trading within three months after the announcement [1] - Board member Yang Zhishan and director Gao Ruibin plan to reduce their holdings by up to 539,000 shares (0.13% of total shares) and 300,000 shares (0.07% of total shares) respectively through centralized bidding within three months after the announcement [1] Group 2 - Senior management members plan to reduce their holdings as follows: Fu Chunyu by up to 619,000 shares (0.15%), Kou Guozhi by up to 460,000 shares (0.11%), Xu Yunlong by up to 220,000 shares (0.05%), Liu Zhenhong by up to 158,000 shares (0.04%), and Zheng Min by up to 120,000 shares (0.03%) through centralized bidding within three months after the announcement [2] - The total number of shares that can be reduced through centralized bidding by any shareholder within any consecutive 90 days shall not exceed 1% of the total shares, and through block trading shall not exceed 2% of the total shares [2]